AAVivo, Inc. Showcases CAR-T Cell Innovation at SITC 2025
HOUSTON /PRNewswire/ -- AAVivo, Inc., recognized for its cutting-edge advancements in biotechnology, has exciting news as it prepares to present at the Society for Immunotherapy of Cancer (SITC) 2025 event scheduled for early November. AAVivo is a pioneering company committed to developing innovative, precision-targeted biotherapeutics aimed at enhancing CAR-T cell generation through advanced gene therapy techniques.
The company has announced it will feature a compelling poster titled, "In Vivo Generation of CD19-Specific CAR-T Cells Using a Novel AAV Gene Therapy Platform to Treat B Cell Malignancies." This research focuses on AAVivo’s lead candidate, AVO-100, which utilizes adeno-associated viruses (AAV) equipped with cell-targeting moieties to create effective CD19-specific CAR-T cells directly within patients’ bodies.
Early preclinical studies have demonstrated that AVO-100 can successfully generate CD19-specific T cells from non-activated T cells collected from human peripheral blood mononuclear cells (PBMCs), both in vitro and in vivo. These CAR-T cells have shown promise in controlling the proliferation of Raji lymphoma in vitro and within NSG mice models, indicating significant potential for treating B cell malignancies.
Dr. Haifeng Chen, Chief Technology Officer and Founder of AAVivo, expressed enthusiasm about the acceptance of their research for presentation at SITC 2025. He stated, "We are pleased that a poster highlighting the potential of our iAAV platform to rapidly enable in vivo generation of CAR-T cells was accepted for presentation at SITC 2025. This opportunity reflects the tremendous potential of AAVivo's innovative technologies and underscores the promise of AVO-100 as a targeted treatment for B-cell malignancies."
The poster presentation details are as follows:
Abstract Number: 1001
Abstract Title: In Vivo Generation of CD19-Specific CAR-T Cells Using a Novel AAV Gene Therapy Platform to Treat B Cell Malignancies
Presenting Author: Haifeng Chen, Ph.D., Chief Technology Officer & Founder, AAVivo, Inc.
Session Date: Friday, Nov. 7
About AAVivo, Inc.
AAVivo, Inc. is an innovative biotechnology firm that focuses on creating precision-targeted biotherapeutics through its proprietary iAAV-based platform. This platform leverages a range of patented technologies, enabling the in vivo generation of CAR-T cells that provide a viable alternative to traditional CAR-T therapies. AAVivo’s next-generation platform showcases several significant innovations, including:
BAC-to-AAV Technology
This technology facilitates large-scale, cost-effective AAV manufacturing, which is crucial for meeting the growing demands of the biotherapeutics market.
Precision AAV Capsid Engineering (PACE)
This method ensures highly specific cell targeting, leading to improved therapeutic outcomes for patients undergoing treatment.
Selective Toxin Packaging (SToP) Platform
With a microRNA safety shield, this platform guarantees the safe delivery of potent therapeutic genes without compromising patient safety.
These innovative approaches collectively enhance yield, maximize potency without lymphodepletion requirements, and improve scalability, making AAV vectors more accessible across various therapeutic indications. AAVivo’s extensive development pipeline includes not only AVO-100 for B-cell malignancies but also AVO-200 and AVO-300, which target solid tumors. This strategic positioning places AAVivo at the forefront of the rapidly evolving gene therapy landscape, offering investors a unique opportunity to engage with a scalable and impact-driven biotechnological platform.
AAVivo is headquartered in Houston, Texas. For further insights about the company and its offerings, prospective stakeholders can visit the company’s official website.
Frequently Asked Questions
What is the main focus of AAVivo, Inc.?
AAVivo, Inc. primarily develops precision-targeted biotherapeutics, focusing on CAR-T cell generation through its innovative iAAV-based platform.
What is the poster presentation about at SITC 2025?
The poster presentation discusses the in vivo generation of CD19-Specific CAR-T cells using AAV technology for treating B cell malignancies.
Who is presenting AAVivo's research at the conference?
The research will be presented by Dr. Haifeng Chen, the Chief Technology Officer and Founder of AAVivo, Inc.
What does AAVivo's technology aim to achieve?
AAVivo aims to provide effective, scalable treatments for B-cell malignancies while enhancing CAR-T therapy outcomes through innovative biotechnological methods.
Where is AAVivo, Inc. located?
AAVivo, Inc. is based in Houston, Texas, where it develops its biotherapeutic technologies and products.
